Last reviewed · How we verify

NCT05225038

Multidimensional Prehabilitation in Pancreatic Surgery for Pancreatic and Periampullary Neoplasms

Completed NA Last updated 19 September 2024
What this trial tests

NA trial testing Exercise in Pancreatic Neoplasms in 23 participants. Completed in 30 October 2023.

Timeline
13 June 2022
Primary endpoint
30 October 2023
30 October 2023

Quick facts

Lead sponsorCase Comprehensive Cancer Center
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposesupportive care
Enrollment23
Start date13 June 2022
Primary completion30 October 2023
Estimated completion30 October 2023
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Case Comprehensive Cancer Center — full company profile →

Who can join

18 and older, any sex, with Pancreatic Neoplasms or Periampullary Carcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Randomized Clinical Trial Investigating Multidimensional Prehabilitation in Pancreatic Surgery for participants with Pancreatic and Periampullary Neoplasms

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Exercise and Nutrition Interventions for Prehabilitation in Hepato-Pancreato-Biliary Cancers: A Narrative Review.
    Christopher CN, Kang DW, Wilson RL, Gonzalo-Encabo P, et al · · 2023 · cited 13× · PMID 38140303 · DOI 10.3390/nu15245044

Verify or expand the search:

Other trials of Exercise

Trials testing the same drug.

Other recruiting trials for Pancreatic Neoplasms

Currently open trials in the same condition.

Other Case Comprehensive Cancer Center trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05225038.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing